viewNemaura Medical Inc

Nemaura Medical licenses Type 2 diabetes weight management mobile app

The app's curriculum gamifies daily tasks and uses high-quality animation and live coaching from its 3D avatar Lena

Healthimation screenshots
Healthimation's 3D avatar Lena exercises along with patients thanks to motion capture technology and over time delivers increasingly tailored messages developed through machine learning

Nemaura Medical Inc (NASDAQ:NMRD) announced Monday that it has licensed the rights to an award-winning diabetes weight management mobile app from Healthimation LLC.

The app provides patients with a 12-week program to manage their weight and pre-diabetes or early diabetes conditions. Healthimation’s curriculum gamifies daily tasks and uses high-quality animation and live coaching from its 3D avatar Lena to encourage users to make healthy behavioral changes related to nutrition and exercise. 

Lena exercises along with patients thanks to motion capture technology and, over time, delivers increasingly tailored messages developed through machine learning.

READ: Nemaura Medical appoints Justin Mclarney as chief finance officer

The program, developed at a US diabetes center, has demonstrated many benefits to a patient’s overall health, including weight reduction; improvements in A1C, lipid profile and blood pressure; and a reduction in medications taken.

“We are delighted and honored to be working with Healthimation to bring diabetic patients an easy-to-use solution that combines our proBEAT CGM product with a clinically validated diabetes management and reversal program,” Nemaura CEO Faz Chowdhury said in a statement. “Our ultimate aim is to help patients with pre-diabetes from becoming diabetic while also providing support to those currently with Type 2 diabetes to potentially reverse their condition.”

Nemaura intends for the program to be combined with proBEAT, the company’s non-invasive continuous glucose monitor (CGM) patch that is expected to launch later this year.

The company believes that combination of the digital program and proBEAT will help patients with Type 2 diabetes reach more beneficial outcomes, help prevent high-risk pre-diabetic patients from becoming diabetic and even possibly lead to diabetes remission. 

The integrated approach offers numerous advantages in breadth of application and depth of features over other competing digital platforms on the weight control and/or diabetes markets, the company said, many of which are more expensive and more invasive.

“Diabetes continues to be one of the largest growing medical problems in the US, and our aim is to provide an unparalleled product and suite of services that can compete favorably with existing products on the market that are less convenient and more invasive for patients,” Chowdhury said.

Nemaura, based in the UK, also makes SugarBEAT, a patented, CE marked, needle-free CGM that is easily applied to the skin via patch. The device transmits blood glucose data to a mobile app to allow for better monitoring or treatment. The company’s BEAT diabetes is a subscription service driven by the data provided by sugarBEAT to provide personalized one-on-one lifestyle coaching and behavior change recommendations.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Nemaura Medical Inc

Price: 4.12 USD

Market: NASDAQ
Market Cap: $94.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...


Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

3 min read